Journal: International journal of molecular sciences

Article Title: Myeloma Microenvironmental TIMP1 Induces the Invasive Phenotype in Fibroblasts to Modulate Disease Progression.

doi: 10.3390/ijms24032216

Figure Lengend Snippet: Figure 1. Tissue inhibitor of metalloproteinase 1 (TIMP1) protein levels. (A) Box plot of TIMP1 protein levels in controls, patients with monoclonal gammopathy of undetermined significance (MGUS), and

Article Snippet: Recombinant TIMP1 (Peprotech, Rocky Hill, NJ, USA), neutralizing anti-TIMP1 antibody (AF970; R&D Systems, Minneapolis, MN, USA), anti-myeloma reagents bortezomib (Selleck Chemicals, Houston, TX, USA), doxorubicin (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), and melphalan (LKT Laboratories, St. Paul, MN, USA) were used for all experiments.

Techniques:

Journal: International journal of molecular sciences

Article Title: Myeloma Microenvironmental TIMP1 Induces the Invasive Phenotype in Fibroblasts to Modulate Disease Progression.

doi: 10.3390/ijms24032216

Figure Lengend Snippet: Figure 2. TIMP1 mRNA levels and TIMP1 protein levels. (A) Box plot of TIMP1 mRNA levels in controls and patients with MGUS or MM. (B) Correlation between TIMP1 concentrations in bone marrow plasma and TIMP1 mRNA levels in bone marrow myeloma cells in patients. Each dot represents an individual patient. TIMP1 mRNA levels in myeloma cells in bone marrow plasma from patients with (C) MGUS and MM, (D) SMM and MM, and (E) MM at newly diagnosis and at CR. (F) TIMP1 mRNA levels in intramedullary myeloma cells and extramedullary myeloma cells. Pairwise comparisons were performed in corresponding patients. Different colors of lines indicate corresponding patients.

Article Snippet: Recombinant TIMP1 (Peprotech, Rocky Hill, NJ, USA), neutralizing anti-TIMP1 antibody (AF970; R&D Systems, Minneapolis, MN, USA), anti-myeloma reagents bortezomib (Selleck Chemicals, Houston, TX, USA), doxorubicin (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), and melphalan (LKT Laboratories, St. Paul, MN, USA) were used for all experiments.

Techniques: Clinical Proteomics, Biomarker Discovery

Journal: International journal of molecular sciences

Article Title: Myeloma Microenvironmental TIMP1 Induces the Invasive Phenotype in Fibroblasts to Modulate Disease Progression.

doi: 10.3390/ijms24032216

Figure Lengend Snippet: Figure 3. TIMP1 mRNA and protein levels. (A) Box plot of TIMP1 mRNA levels and (B) TIMP1 protein levels among different cytogenetic abnormalities.

Article Snippet: Recombinant TIMP1 (Peprotech, Rocky Hill, NJ, USA), neutralizing anti-TIMP1 antibody (AF970; R&D Systems, Minneapolis, MN, USA), anti-myeloma reagents bortezomib (Selleck Chemicals, Houston, TX, USA), doxorubicin (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), and melphalan (LKT Laboratories, St. Paul, MN, USA) were used for all experiments.

Techniques:

Journal: International journal of molecular sciences

Article Title: Myeloma Microenvironmental TIMP1 Induces the Invasive Phenotype in Fibroblasts to Modulate Disease Progression.

doi: 10.3390/ijms24032216

Figure Lengend Snippet: Figure 4. Overall survival (OS), progression-free survival (PFS), and post-progression survival (PPS) in patients with newly diagnosed multiple myeloma (NDMM) divided into two groups. (A) OS. (B) PFS. (C) PPS. Black line, TIMP1 protein levels in bone marrow plasma < 290 ng/mL; red line, TIMP1 protein levels ≥290 ng/mL. (D) OS. (E) PFS. Black line, TIMP1 mRNA levels in bone marrow myeloma cells < 0.035; red line, TIMP1 mRNA levels ≥0.035.

Article Snippet: Recombinant TIMP1 (Peprotech, Rocky Hill, NJ, USA), neutralizing anti-TIMP1 antibody (AF970; R&D Systems, Minneapolis, MN, USA), anti-myeloma reagents bortezomib (Selleck Chemicals, Houston, TX, USA), doxorubicin (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), and melphalan (LKT Laboratories, St. Paul, MN, USA) were used for all experiments.

Techniques: Clinical Proteomics

Journal: International journal of molecular sciences

Article Title: Myeloma Microenvironmental TIMP1 Induces the Invasive Phenotype in Fibroblasts to Modulate Disease Progression.

doi: 10.3390/ijms24032216

Figure Lengend Snippet: Figure 5. Fibroblast invasive capacity. Three-dimensional matrix invasion assays were used to evaluate the invasive capacity of (A) OUMS-36T-3F and (B) HS-5 with or without recombinant TIMP1 (0.5 µg/mL) or anti-TIMP1 antibodies (4.0 µg/mL). Blue bar, control; orange bar, recombinant TIMP1; yellow bar, anti-TIMP1 antibodies. Experiments were performed seven times. Error bars show standard deviations (SDs). Representative images of OUMS-36T-3F and HS-5 cells cultured with or without recombinant TIMP1 or anti-TIMP1 antibodies. The yellow arrows point to the spheres.

Article Snippet: Recombinant TIMP1 (Peprotech, Rocky Hill, NJ, USA), neutralizing anti-TIMP1 antibody (AF970; R&D Systems, Minneapolis, MN, USA), anti-myeloma reagents bortezomib (Selleck Chemicals, Houston, TX, USA), doxorubicin (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), and melphalan (LKT Laboratories, St. Paul, MN, USA) were used for all experiments.

Techniques: Recombinant, Control, Cell Culture

Journal: International journal of molecular sciences

Article Title: Myeloma Microenvironmental TIMP1 Induces the Invasive Phenotype in Fibroblasts to Modulate Disease Progression.

doi: 10.3390/ijms24032216

Figure Lengend Snippet: Figure 6. Invasive capacity of (A) OUMS-36T-3F and (B) HS-5 cells incubated with BM plasma and IgG control or neutralizing anti-TIMP1 antibodies. Blue line, IgG control; orange line, anti-TIMP1 antibodies. Representative images of OUMS-36T-3F and HS-5 cells cultured with BM plasma from patient UPN179 at diagnosis (TIMP1 protein level: 413.71 ng/mL) with IgG control or anti-TIMP1 antibodies.

Article Snippet: Recombinant TIMP1 (Peprotech, Rocky Hill, NJ, USA), neutralizing anti-TIMP1 antibody (AF970; R&D Systems, Minneapolis, MN, USA), anti-myeloma reagents bortezomib (Selleck Chemicals, Houston, TX, USA), doxorubicin (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), and melphalan (LKT Laboratories, St. Paul, MN, USA) were used for all experiments.

Techniques: Incubation, Clinical Proteomics, Control, Cell Culture, Biomarker Discovery

Journal: International journal of molecular sciences

Article Title: Myeloma Microenvironmental TIMP1 Induces the Invasive Phenotype in Fibroblasts to Modulate Disease Progression.

doi: 10.3390/ijms24032216

Figure Lengend Snippet: Figure 8. Gene expression in OUMS-36T-3F cells with or without recombinant TIMP1 (0.5 µg/mL). (A) q-PCR analysis of genes which are involved in cancer-associated fibroblast (CAF) formation. (B) Gene ontology analysis. (C,D) Gene set enrichment analysis (GSEA).

Article Snippet: Recombinant TIMP1 (Peprotech, Rocky Hill, NJ, USA), neutralizing anti-TIMP1 antibody (AF970; R&D Systems, Minneapolis, MN, USA), anti-myeloma reagents bortezomib (Selleck Chemicals, Houston, TX, USA), doxorubicin (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), and melphalan (LKT Laboratories, St. Paul, MN, USA) were used for all experiments.

Techniques: Gene Expression, Recombinant